JP5000521B2 - 脱保護の方法 - Google Patents

脱保護の方法 Download PDF

Info

Publication number
JP5000521B2
JP5000521B2 JP2007534071A JP2007534071A JP5000521B2 JP 5000521 B2 JP5000521 B2 JP 5000521B2 JP 2007534071 A JP2007534071 A JP 2007534071A JP 2007534071 A JP2007534071 A JP 2007534071A JP 5000521 B2 JP5000521 B2 JP 5000521B2
Authority
JP
Japan
Prior art keywords
fdg
protected
acid
compound
deprotection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007534071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515793A5 (enExample
JP2008515793A (ja
Inventor
グリック，ジュリアン
オズボーン，ナイジェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2008515793A publication Critical patent/JP2008515793A/ja
Publication of JP2008515793A5 publication Critical patent/JP2008515793A5/ja
Application granted granted Critical
Publication of JP5000521B2 publication Critical patent/JP5000521B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
JP2007534071A 2004-10-05 2005-09-23 脱保護の方法 Expired - Fee Related JP5000521B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0422004.2 2004-10-05
GBGB0422004.2A GB0422004D0 (en) 2004-10-05 2004-10-05 Method of deprotection
PCT/GB2005/003692 WO2006037950A1 (en) 2004-10-05 2005-09-23 Method of deprotection

Publications (3)

Publication Number Publication Date
JP2008515793A JP2008515793A (ja) 2008-05-15
JP2008515793A5 JP2008515793A5 (enExample) 2008-11-06
JP5000521B2 true JP5000521B2 (ja) 2012-08-15

Family

ID=33428035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007534071A Expired - Fee Related JP5000521B2 (ja) 2004-10-05 2005-09-23 脱保護の方法

Country Status (6)

Country Link
US (1) US7714115B2 (enExample)
EP (1) EP1797029A1 (enExample)
JP (1) JP5000521B2 (enExample)
CN (1) CN101035755B (enExample)
GB (1) GB0422004D0 (enExample)
WO (1) WO2006037950A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070260267A1 (en) * 2002-10-07 2007-11-08 Nicoson Zachary R Localizing obturator
KR101497406B1 (ko) * 2006-12-21 2015-03-02 니혼 메디피직스 가부시키가이샤 방사성 화상 진단제
JP5518337B2 (ja) 2006-12-27 2014-06-11 日本メジフィジックス株式会社 放射性ハロゲン標識有機化合物の前駆体化合物の製造方法
CN101636183B (zh) * 2007-02-13 2014-03-19 日本医事物理股份有限公司 放射性诊断显像剂的制备方法
EP2005970A1 (de) 2007-06-22 2008-12-24 Berlin Science Partners GmbH i.V. Bildgebende Diagnostik durch Kombination von Kontrastmitteln
US8043316B2 (en) 2008-05-02 2011-10-25 Suros Surgical Systems, Inc. Adjustable spacer
GB0905515D0 (en) * 2009-03-31 2009-05-13 Ge Healthcare Ltd Radiolabelling methods
EP2501663A2 (en) * 2009-11-17 2012-09-26 Piramal Imaging SA Method for production of f-18 labeled glutamic acid derivatives
EP2582713A1 (en) * 2010-06-17 2013-04-24 MSD Oss B.V. (11 beta,17 alpha)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one
KR20130132892A (ko) * 2010-12-29 2013-12-05 지이 헬쓰케어 리미티드 용리제 용액
US9101895B2 (en) 2011-04-15 2015-08-11 General Electric Company System for mixing and dispersing microbubble pharmaceuticals
KR101221483B1 (ko) * 2011-05-13 2013-01-16 서강대학교산학협력단 Ｆ-18 표지 방사성의약품 합성 장치 및 방법
GB201411569D0 (en) 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
RU2623163C2 (ru) * 2011-12-21 2017-06-22 ДжиИ ХЕЛТКЕР ЛИМИТЕД Композиция 18f- флуцикловина в цитратных буферах
EP3151751A4 (en) * 2014-06-06 2018-02-21 The Regents of the University of California Self-shielded, benchtop chemistry system
LT3481804T (lt) 2016-06-10 2025-02-25 The Johns Hopkins University Radioaktyviai pažymėto prostatos specifinio membranos antigeno (psma) inhibitoriaus [18f]dcfpyl pagerinta sintezė
ES2916840T3 (es) * 2016-12-07 2022-07-06 Univ Degli Studi Di Bari Aldo Moro Formulaciones estables de F-DOPA y usos de las mismas
JP7159157B2 (ja) * 2017-06-23 2022-10-24 日本メジフィジックス株式会社 放射性フッ素標識化合物の製造方法および放射性医薬の製造方法
WO2022196734A1 (ja) * 2021-03-17 2022-09-22 Tdk株式会社 含フッ素化合物および造影剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135683A (en) * 1991-03-28 1992-08-04 Arco Chemical Technology, L.P. Process for producing a deprotected alkoxylated polyol
US5393908A (en) 1992-06-25 1995-02-28 Satyamurthy; Nagichettiar Synthesis of N-formyl-3,4-di-t-butoxycarbonyloxy-6-(trimethylstannyl)-L-phenylalanine ethyl ester and its regioselective radiofluorodestannylation to 6-[18 F]fluoro-L-dopa
DE4330889C2 (de) * 1993-09-11 2002-10-31 Emtec Magnetics Gmbh Verfahren zur Wiedergewinnung von Rohmaterialien aus magnetischen Aufzeichnungsträgern
US5922810A (en) * 1995-07-31 1999-07-13 Fmc Corporation Deprotection of protected functional polymers
BE1010280A3 (fr) * 1996-05-02 1998-05-05 Coincidence S A Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose.
DE10104250A1 (de) * 2001-01-31 2002-08-14 Deutsches Krebsforsch Markierungsfähige Verbindungen zur einfachen Synthese von 3'-[18F]Fluor-3'-deoxythymidin und Verfahren zu deren Herstellung
EP1356827A1 (en) 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
US7022872B2 (en) * 2003-12-19 2006-04-04 Molecular Technologies, Inc. Method for making fluorine labeled L-Dopa

Also Published As

Publication number Publication date
US20080076914A1 (en) 2008-03-27
US7714115B2 (en) 2010-05-11
WO2006037950A1 (en) 2006-04-13
EP1797029A1 (en) 2007-06-20
CN101035755B (zh) 2011-12-21
GB0422004D0 (en) 2004-11-03
CN101035755A (zh) 2007-09-12
JP2008515793A (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
JP5000521B2 (ja) 脱保護の方法
US20230331640A1 (en) Production method for radiolabeled aryl compound
KR102137348B1 (ko) 시트레이트 완충제 내 18ｆ―플루시클로빈 조성물
US9567350B2 (en) Process for the preparation of chelated compounds
CN104762666A (zh) 双重运行盒
MX2014006548A (es) Produccion de compuestos 18f-etiquetados que comprenden paso de desproteccion hidrolitica y extraccion de fase solida.
KR20170027732A (ko) 신규 제제 및 합성 방법
RU2620598C2 (ru) Способ синтеза 18F-меченых биомолекул
EP2766326B1 (en) Method for the synthesis of 18f-labelled biomolecules
EP2793954B1 (en) 18f-fluciclovine compositions in citrate buffers
JP4172393B2 (ja) 保護されたチロシン誘導体、その製造方法、及びｏ−（２−〔１８ｆ〕−フルオロエチル）−ｌ−チロシン製造のためのその使用
EP2646411B1 (en) Preparation of pet precursor
HK40111817A (en) Production method for radiolabeled aryl compound
HK40011012A (en) 18f - fluciclovine compositions in citrate buffers
NZ624250B2 (en) 18f-fluciclovine compositions in citrate buffers
HK1197368A (en) 18f - fluciclovine compositions in citrate buffers
NZ624250A (en) 18f-fluciclovine compositions in citrate buffers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080917

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120417

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120516

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150525

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees